We demonstrated the clinical relevance of the LINC00152/PDE4D/cAMP/Ca2+/ferroptosis axis and showed that higher LINC00152 levels are associated with worse survival in multiple cohorts of endocrine therapy-treated ER+ breast cancer patients as well as other cancers. This evidence concerns the gene CYTOR and breast carcinoma.